Table 1

 Trials included in the meta-analysis

Study and referenceDrugFollow upAntiplatelet treatment*Definition of percutaneous revascularisation†Angiographic binary restenosis definitionDeath
*In addition to aspirin; †revascularisation was one component (the most frequent) of the composite end point (major adverse cardiac events).
ACC, American College of Cardiology; ASPECT, Asian paclitaxel eluting stent clinical trial; C-SIRIUS, Canadian sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; CV, cardiovascular; DIABETES, diabetes and sirolimus eluting stent trial; ELUTES, European evaluation of paclitaxel eluting stent; ENDEAVOR, randomised, controlled trial of the Medtronic Endeavor drug (ABT-578) eluting coronary stent system versus the Taxus paclitaxel eluting coronary stent system in de novo native coronary artery lesions; E-SIRIUS, European sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; FUTURE, first use to underscore reduction in restenosis with everolimus; MI, myocardial infarction; NA, not available; PATENCY, paclitaxel coated logic stent for the cytostatic prevention of restenosis; RAVEL, randomised study with sirolimus coated BX velocity balloon expandable stent in the treatment of patients with de novo native coronary lesions; SCANDSTENT, randomised multicentre comparison of sirolimus versus bare metal stent implantation in complex coronary lesions; SCORE, study to compare restenosis rate between quest and quads-QP2; SES-SMART, randomised comparison of a sirolimus eluting stent and a standard stent in the prevention of restenosis in small coronary arteries; SIRIUS, sirolimus eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions; TAXUS, treatment of de novo coronary disease using a single paclitaxel eluting stent; TLR, target lesion revascularisation; TVR, target vessel revascularisation.
Trials in the sirolimus (and analogues) subgroup
RAVEL38Sirolimus1 yearClopidogrel or ticlopidine 8 weeksTLR: clinically driven or evidence of restenosisIn-target lesion including proximal and distal edge; at 6 monthsAny
SIRIUS39Sirolimus1 yearClopidogrel 3 monthsTLR: clinically driven and restenosis >70%In segment zone including margins 5 mm distal and proximal; at 8 monthsAny
E-SIRIUS40Sirolimus9 monthsClopidogrel or ticlopidine 2 monthsTLR: clinically drivenIn lesion including 5 mm proximal and distal edge; at 8 monthsAny
C-SIRIUS41,42Sirolimus1 yearClopidogrel 2 monthsTLR: clinically driven including stenosis >70%In-stent lesion; at 8 monthsAny
FUTURE I/II45Everolimus6 monthsNATLRIn segment; at 6 monthsAny
SES-SMART59Sirolimus8 monthsClopidogrel 2 monthsTLRIn segment; at 8 monthsAny
SCANDSTENT44Sirolimus1 yearNATLRIn-stent lesion; at 6 monthsAny
DIABETES43Sirolimus9 monthsNATLRIn segment; at 9 monthsAny
ENDEAVOR II10Biolimus1 yearNATVRAny
Trials in the paclitaxel (and analogues) subgroup
SCORE46QP2 is 7-hexanoyltaxol1 yearTiclopidine or clopidogrel 1–6 monthsTLRIn stent; at 6 monthsCardiac death
TAXUS I47,48Slow release polymer based paclitaxel1 yearClopidogrel 6 monthsTVR: indication not reported, only Q wave MIIn-stent lesion (edges excluded); at 6 monthsAny
ASPECT52Non-polymer based paclitaxel low or high dose6 monthsClopidogrel or ticlopidine 1 or 6 months, or cilostazolTLR: ischaemia drivenIncluding proximal and distal references; at 4–6 monthsAny
TAXUS II48,49Slow or moderate release polymer based paclitaxel1 yearClopidogrel (or ticlopidine) 6 monthsTVR: indication not reportedIn total analysis segment including 5 mm proximal and distal edge; at 6 monthsCardiac death
TAXUS IV48,60Slow release polymer based paclitaxel9 monthsClopidogrel for 6 monthsTVR: ischaemia drivenIn analysis segment including proximal and distal edge; at 9 monthsCardiac death
ELUTES55Non-polymer based paclitaxel 4 doses1 yearClopidogrel 3 monthsTLR: clinically drivenIn stent; at 6 monthsAny
DELIVER53,54Non-polymer based paclitaxel1 yearClopidogrel 3 monthsTVRIn segment including 5 mm proximal and distal; at 8 monthsCardiac death
PATENCY56Non-polymer based paclitaxel9 monthsClopidogrel 3 monthTLRIn stent? At 9 monthsAny
TAXUS V61Slow release polymer based paclitaxel9 monthsNATVR: indication not reportedIn stent? At 9 monthsCardiac death
TAXUS VI62Moderate release polymer based paclitaxel9 monthsNATVR: indication not reportedIn segment? At 9 monthsCardiac death